Showing 5951-5960 of 6035 results for "".
- Retinal Changes on OCT Angiography May Flag Early Alzheimer’shttps://modernod.com/news/retinal-changes-on-oct-angiography-may-flag-early-alzheimers/2480158/Microvascular changes in the retina detected by using noninvasive optical coherence tomography (OCT) angiography align well with imaging and biomarker evidence of preclinical Alzheimer’s disease, a new study shows, according to a Medscape
- Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launchhttps://modernod.com/news/kala-pharmaceuticals-strengthens-commercial-organization-in-preparation-for-first-product-launch/2480159/Kala Pharmaceuticals announced the following key commercial hires in preparation for the potential approval and launch of Inveltys, a twice-daily steroid eye drop in development for the treatment of inflammation and pain following ocular surgery: Kathleen McCann Kline, Vice President
- California Optometrists Caution Patients About Unapproved, Online Vision Tests After FDA Warninghttps://modernod.com/news/california-optometrists-caution-patients-about-unapproved-online-vision-tests-after-fda-warning/2480161/The California Optometric Association cautioned California consumers that self-administered “vision tests” conducted online come with significant safety concerns and appear to violate federal law, according to a news release. In a letter to the California Attorney General, the organization
- Bausch + Lomb Launches Lumify, the First OTC Redness Relieving Eye Drop With Low-Dose Brimonidinehttps://modernod.com/news/bausch-lomb-launches-lumify-the-first-otc-redness-relieving-eye-drop-with-low-dose-brimonidine/2480169/Bausch + Lomb announced the launch of Lumify (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. “With the availability of Lumify, consumers now have an in
- Sylentis Announces New Data on the Treatment of Allergic Conjunctivitishttps://modernod.com/news/sylentis-announces-new-data-on-the-treatment-of-allergic-conjunctivitis/2480172/At the ARVO meeting, Sylentis presented preclinical results on its RNAi therapy, demonstrating how SYL116011 acts on seasonal ocular allergies SYL116011, which is being researched for ocular allergies caused by pollen, reduces the symptoms related to allergy, such as swelling and tearing,
- Sylentis Presents New Results for the Treatment of AMDhttps://modernod.com/news/sylentis-presents-new-results-for-the-treatment-of-amd/2480173/Sylentis presented preclinical results of a new topically administered molecule (SYL1801), indicated for the treatment of age-related macular degeneration (AMD), at the ARVO meeting. Sylentis presented the abstract “Topical administration of siRNA targeting NRARP as a new treatment
- Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC for the Treatment of Glaucomahttps://modernod.com/news/ocular-therapeutix-announces-treatment-of-first-patient-in-phase-1-clinical-trial-of-otx-tic-for-the-treatment-of-glaucoma-and-ocular-hypertension/2480177/Ocular Therapeutix announced the treatment of the first patient in a phase 1, open-label, proof-of-concept clinical trial being conducted in the United States for OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection for the reduction of IOP in patients with glaucoma
- Glaucoma Research Foundation Speeds Search for a Curehttps://modernod.com/news/glaucoma-research-foundation-speeds-search-for-a-cure/2480187/Glaucoma Research Foundation has announced the celebration of its 40th anniversary year, the board approval of its new strategic plan, and an expanded capital campaign designed to accelerate research towards a cure. Commemorated at an April 24 annual dinner at the War Memorial in San F
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- USC Roski Eye Institute Scientists Present Latest Research at the ARVO Annual Meetinghttps://modernod.com/news/usc-roski-eye-institute-scientists-present-latest-research-at-the-arvo-annual-meeting/2480198/What do nanophotoswitches, lipid nanoparticles, and mapping the brain have in common? They are among the future-forward areas of vision research being investigated by USC Roski Eye Institute